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Background: Despite clear evidence for the effectiveness of oral anticoagulation (OA) in patients with atrial
fibrillation (AF), there is evidence for the underutilisation of this therapy in the secondary stroke prevention.
We therefore investigate the link between the use of OA in stroke patients with AF and favourable clinical
outcome following the acute event.
Methods: The study population was determined by identifying the overlap of two different databases: a stroke
registry and claims data of a health insurance company. Baseline data originated from the registry; documented
dementia and the prescriptions for OA were derived from the insurance database. Patients with AF, minor physical
impairment, and evidence of more than 30 days without further hospitalisation within the subsequent 90 days after
the acute event were selected for the analysis.
Results: 1828 patients were selected (mean age 77.6 years), 1064 patients (58.2%) were female. 827 patients (45%)
received a prescription for OA. The following factors were independently associated with no prescription for oral
anticoagulants: increased age (OR: 0.54, CI: 0.46-0.63; P < 0.0001), female sex (OR: 0.77, CI: 0.63-0.94; P < 0.011),
worsening disability status at discharge (OR: 0.88, CI: 0.81-0.96; P < 0.006), and documented dementia (OR: 0.54,
CI: 0.39-0.73; P < 0.001). Conversely, treatment in a neurological department was associated with prescription for
OA (OR: 1.47, CI: 1.19-1.81; P < 0.003).
Conclusions: In more than half of the patients with AF who suffered a stroke OA was not prescribed. The factors
associated with reluctance in prescribing anticoagulants are increasing age, female sex, treatment at a non-neurological
department, worsening disability, and dementia.
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The high risk for recurrences in cardioembolic stroke
due to atrial fibrillation (AF) renders secondary preven-
tion mandatory [1]. Oral anticoagulation (OA) has been
proven as an effective treatment for this condition [1-5].
In recent investigations new tools for risk stratification
have been developed [6]. Accordingly, current guidelines
for patients with cardioembolic stroke and AF recommend
oral anticoagulant treatment [7]. A favourable risk/benefit
ratio using this regimen was also proven in elderly patients
[8]. However, registry data shows an underutilisation of* Correspondence: christian.tanislav@neuro.med.uni-giessen.de
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unless otherwise stated.this treatment option [9-11]. Lack of knowledge of
current guidelines, concern for the risk of bleeding,
socio-demographic factors (increased age, ability to
cope with everyday tasks) and clinical factors (neuro-
logical deficits, dementia, and previous bleedings) are
suspected to influence the low rates in the usage of OA
in the clinical practice.
In this study, we investigated factors which might have
impact on the decision to use OA in stroke patients with
AF with a favourable clinical outcome after the acute
event. For this reason, we analysed prescriptions docu-
mented nationwide in an insurance dataset in the
Federal state of Hesse, Germany, together with baseline
data, derived from a large comprehensive stroke registry.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The presented study is based on data generated by the
study of two different databases and where patient infor-
mation records overlapped:
(1) Registry data (2004–2010) of the Institute of
Quality Assurance Hesse (Geschäftsstelle für
Qualitätssicherung, GQH) [12]. The GQH database
is an obligatory nationwide hospital-based registry
that covers more than 95% of all ischemic strokes,
TIA and intracerebral haemorrhages in a commu-
nity of more than 6 million inhabitants of Hesse,
Germany [13]. The GQH-data include details of
acute inpatient treatment, as well as factors proved
to be relevant for the course and the prognosis of
stroke [12,13].
(2) Claims data from a nationwide statutory health
insurance company in Germany (AOK Hessen).
The insurance database includes date of death and
all billed services, as well as services provided by
nursing care insurance. Insurance data between
2005 and 2007 were available for the analysis.Ethical issues
In Germany the acquisition of data for quality assurance
reasons is regulated by law and implemented as a guide-
line, which is elaborated by the Federal Joint Committee
for hospital quality assurance in accordance with Volume V
of the Social Insurance Code (§137 SGB V and §135a SGB
V). Based on this regulation the Hesse State Hospital Law
contains a provision that allows the GQH to record such
data legally. The publication of aggregate quality assurance
data has also been cleared with the Hesse Data Protection
Commissioner, so no data protection problem arises here
either [13].
The protocol of the present study was reviewed and
approved by the ethical committee of the medical faculty
of the Justus Liebig University Giessen.Patient selection
Patients ≥ 18 years of age with an index event consistent
of stroke or transient ischemic attack, diagnosed atrial fib-
rillation, a minimal physical impairment (modified Rankin
scale (mRS) ≤3 on discharge) and direct discharge after
acute treatment or referral subsequently to a rehabilitation
facility were identified from the stroke registry. Among
these patients, individuals affiliated to the insurance com-
pany were identified within the dataset in a pseudonymous
manner according to the following matching criteria: sex,
date of birth, date of admission and admitting hospital.
Patients with evidence of at least a 30-day period free of
additional hospitalisation within the 90 days following the
initial acute treatment were considered for the analysis.Parameters and outcome measurements
For comparing baseline characteristics the following pa-
rameters were considered: age, sex, ischaemic stroke ver-
sus transient ischemic attack (TIA), previous stroke,
vascular risk profile (hypertension and diabetes), disabil-
ity status on discharge as assessed by mRS, treatment in
a neurological department and comorbidities occurring
during hospitalisation.
To determine the therapeutic management for second-
ary stroke prevention we analysed prescriptions for oral
anticoagulants (including phenprocoumaron, warfarin and
coumadin) within a time frame of 90 days after discharge
from the acute unit or the rehabilitation facility. Addition-
ally documentation for dementia was determined. For this
purpose ICD10 codes within the insurance dataset were
considered: dementia by Alzheimer’s disease (F00.-, G30.-),
vascular dementia (F01.-), secondary dementia (F02.-) and
undetermined dementia (F.03).
Statistical evaluation
Absolute and relative frequencies were calculated based on
cross-tables. For testing normal distribution a Kolmogorov-
Smirnof Test was applied. Normal distributed variables
were tested using a t-test. To compare non-normal dis-
tributed data a Mann–Whitney U-test was applied. For
comparing frequency data a Fisher’s exact test was used.
Factors associated with the outcome in the unadjusted
analyses were entered into a logistical analysis for prov-
ing parameters in the equation.
Results
Within the GQH dataset 6261 documented cases were
identified as stroke patients suffering of atrial fibrillation
with a mRS ≤ 3 and no subsequent referral to another de-
partment. Out of these 6261 patients, 2101 were identified
within the insurance’s dataset. 1828 patients were included
in the final analysis as they fulfilled the inclusion criteria
(30 days free interval of further hospitalisation and no
recurrent stroke with the subsequent 90 days after
discharge and complete 90 day follow up). For details see
also Figure 1.
The mean age of the study population was 77.6 years,
1064 (58.2%) were female. In 639 (35%) patients a transi-
ent ischemic attack (TIA) was documented as index stroke
event. 1243 (68%) patients were treated in a neurological
department and in 205 (11.2%) patients documentation
for dementia was evident. In 827 patients (45%) a
prescription for OA was identified. With increasing age
the proportion of patients treated with OA decreases;
while in the age category below 75 years the patients with
prescription for OA represented the majority, above this
age non-prescription predominated (Figure 2).
Factors such as advanced age, female sex, TIA, worse dis-
ability status on discharge, no treatment in a neurological
44488 cases without documented  atrial fibrillation
4505 cases with documented mRank>3 on discharge
1353 cases with documented subsequent referral to an 
rehabilitation department  
4160 cases referring patients 
affiliated to other insurances 
2101 cases referring patients 
affiliated to insurance 
56607 cases of ischemic stroke or TIA, identified in the hessian 
registry (2005-2007)  
6261 cases   
1001 cases without documented 
prescription for anticoagulants  
827 cases with documented 
prescription for anticoagulants  
1828 cases included in the final analysis 
Screening within the insurance-dataset:
119 cases of recurrent stroke   
3 without complete 90 follow-up
103 deceased within the 90 day follow-up 
48 cases without at least 30 days free interval of 
further hospitalisation within the subsequent 90 days.
Figure 1 Patients selection within the stroke registry and after conjunction to the insurance data base.
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with no prescription for oral anticoagulants (Table 1). For
identifying independent factors, parameters associated in
the univariate analysis were entered into a logistical re-
gression analysis (age, sex, disability status as assessed
on discharge, treatment in a neurological department
and documented dementia). As a cerebrovascular event
classified as TIA might directly influence the clinicalFigure 2 Distribution of patients (stratified by age) with prescriptionoutcome, which is indicated by the factor mRS, the par-
ameter TIA was not included in the logistical regression
analysis. Independently associated with a non-prescription
decision for oral anticoagulants in the secondary stroke
prevention were: increased age (OR: 0.54, CI: 0.46-0.63;
P < 0.0001), female sex (OR: 0.77, CI: 0.63-0.94; P < 0.011),
worse disability status on discharge (OR: 0.88, CI: 0.81-
0.96; P < 0.006) and documented dementia (OR: 0.54,for OA versus without.





P OR* (95% CI)




Age (years) median/mean (SD) 77.61 (±8.6) 75.01 (±8.1) 79.75 (±8.5) < 0.001
< 65 years 126 (6.9%) 79 (9.6%) 47 (4.7%) < 0.001 2.14 (1.48-3.11)
65-75 years 537 (29.4%) 323 (39.1%) 214 (21.4%) < 0.001 2.36 (1.99-2.90)
> 75 years 1165 (63.7%) 425 (51.4%) 740 (73.9%) < 0.001 0.37 (0.31-0.45)
Sex
Male 764 (41.8%) 398 (48.1%) 366 (36.6%) < 0.001 ref. category
Female 1064 (58.2%) 429 (51.9%) 635 (63.4%) < 0.001 0.62 (0.52-0.75)
Risk factors
Hypertension 1444 (79.0%) 660 (79.8%) 784 (78.3%) 0.4 1.09 (0.87-1.37)
Diabetes mellitus 530 (29.0%) 240 (29.0%) 290 (29.0%) 0.9 1.00 (0.82-1.23)
Diagnosis
TIA 639 (35.0%) 260 (31.4%) 379 (37.9%) < 0.001 0.75 (0.62-0.91)
Previous stroke 433 (23.7%) 179 (21.6%) 254 (25.4%) 0.062 0.81 (0.65-1.01)
mRS as assessed on discharge
0 557 (30.5%) 282 (34.1%) 275 (27.5%) 0.002 1.37 (1.19-1.67)
1 478 (26.1%) 226 (27.3%) 252 (25.2%) 0.3 1.18 (0.91-1.38)
2 403 (22.0%) 174 (21.0%) 229 (22.9%) 0.3 0.90 (0.72-1.12)
3 390 (21.3%) 145 (17.5%) 245 (24.5%) < 0.001 0.66 (0.52-0.82)
Median, range 1 (0–3) 1 (0–3) 1 (0–3)
Treatment in a neurological department 1243 (68.0%) 611 (73.9%) 632 (63.1%) < 0.001 1.65 (1.35-2.02)
Comorbidities occurring while hospitalisation
Intracranial bleeding 8 (0.4%) 5 (0.6%) 3 (0.3%) 0.3 2.02 (0.48-8.49)
Extracranial bleeding 7 (0.4%) 4 (0.5%) 3 (0.3%) 0.5 1.61 (0.36-7.24)
Recurrent stroke/TIA 17 (0.9%) 12 (1.5%) 5 (0.5%) 0.04 2.93 (1.03-8.36)
Seizure 6 (0.3%) 0 (0%) 6 (0.6%) 0.03 not applicable
Pneumonia 42 (2.3%) 18 (2.2%) 24 (2.4%) 0.8 0.91 (0.49-1.69)
Documented dementia within the insurance database# 241 (13.2%) 67 (7.2%) 174 (14.2%) < 0.001 0.42 (0.31-0.56)
*Value calculated in a Chi Square Test of Independence.
#dementia documented within the insurance database on discharge or within 90 days after discharge; considered were the following ICD10 codes: dementia by
Alzheimer’s disease (F00.-), vascular dementia (F01.-, G30), secondary dementia (F02.-) and undetermined dementia (F.03).
AK refers to anticoagulants.
TIA refers to transient ischaemic attack.
mRS refers to modified Rankin scale.
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logical department was associated with a prescription
decision (OR: 1.47, CI: 1.19-1.81; P < 0.003), (Table 2).
Discussion
In studying a group of stroke patients with AF with a best
case scenario, we detected a low rate (45%) of prescrip-
tions for OA. This is a surprising result, considering the
selected patients were most suitable for OA therapy; after
the acute stroke they all had a favorable disability status
(mRS ≤ 3 as assessed on discharge). With increasing age
the proportion of patients treated with OA decreased(Figure 2). While advanced age, female sex, worse
disability status and dementia were associated with a
non-prescription, treatment in a specialized neuro-
logical department facilitated the therapeutic decision
for OA in the secondary prevention.
Considering the low rate of prescriptions for OA in our
study and the bulk of evidence, indicating the necessity for
this therapy, the situation in the broad care delivery seems
to follow particular rules [2,4,5,14,15]. Even though the
evidence provided in the Birmingham Atrial Fibrillation
Treatment of the Aged (BAFTA) indicates superiority of
OA against aspirin in elderly patients, increased age was
Table 2 Logistical regression analysis (parameters
associated with prescription/non-prescription in the
univariate analysis (p < 0.05) were considered)
OR (95% CI) P
Age (in categories) < 0.001
Higher age 0.54 (0.46-0.63)




mRS as assesses on
Discharge (in categories)
0.006
Higher disability 0.88 (0.81-0.96)
Lower disability 1.13 (1.04-1.38)










#dementia documented within the insurance database on discharge or within
90 days after discharge; considered were the following ICD10 codes: dementia
by Alzheimer’s disease (F00.-), vascular dementia (F01.-, G30), secondary
dementia (F02.-) and undetermined dementia (F.03).
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in comparison to recent trials, which investigated the
efficacy of OA in AF, patients selected for OA in our
study were older (median 76 versus 70–71 years)
[2,4,14]. Nevertheless, 55% of the patients seen were not
prescribed OA which might be explained by the generally
advanced age range (median 79 years) in patients en-
countered in daily practice.
A further aspect which needs to be taken into consi-
deration is the risk for bleeding. This risk increases with
increasing age [16,17]. Particularly in the case of intra-
cranial hemorrhages, the risk increases substantially for
patients over 75 years in age [15,18]. This clearly influ-
ences the practitioner’s decision-making when selecting
treatment options. Whereas, in the age category from 75
to 79 years half of the patients are treated by OA, in
individuals ≥80 years the decision for an OA is consider-
ably less frequent (Figure 2). Weighing all the arguments
for OA for secondary stroke prevention in relation to
the safety concerns, the reluctance to prescribe OA for
elderly patients is understandable. A clinician’s treatment
decisions are guided by balancing effectiveness against
risk to harm. As indicated by our results, safety concerns
prevail. In order to minimize difficulties in the adequate
selection of patients for OA, clear evidence on efficacy
and safety among patients occurring in the real worldare required. Future studies should address treatment
decisions for elderly patient care. Furthermore, studies
proving treatment effects in the secondary stroke pre-
vention are necessary.
However, age was not the only determinant which con-
tributed to the low usage rate of OA among stroke pa-
tients with AF in the clinical practice. An additional
independent factor in facilitating the prescription for OA
therapy was the treatment of the acute event in a special-
ized neurological department. Therapeutic recommenda-
tions from specialized departments seem to be of
considerable relevance for the subsequent secondary
stroke prevention emphasizing the need to establish
such units. Furthermore, specific educational programs
for general practitioners and specialists who are in-
volved in the treatment of stroke patients with AF, ap-
pears necessary.
Concerning the disability status, there is no conclusive
reason for not prescribing OA in our study. All selected
patients were not severely disabled (mRS ≤ 3 as assessed
on discharge), which implies the patient’s ability to walk
independently as well as minor assistance needed in
coping with daily tasks. However, even in this range a
slight deterioration results in the decision for an alterna-
tive therapy to OA.
The low rate of OA prescriptions in patients with docu-
mented dementia is not surprising, given to the need for
monitoring this treatment precisely. However, there is no
credible argument to withhold an effective therapy to
patients with cognitive decline. Given the availability of
newer anticoagulants with slightly less treatment moni-
toring requirements, these patients can benefit from
OA usage in the future.
The identified factors might not be sufficient to
entirely explain the low rate of patients selected for OA.
The influence of further factors including cerebral
imaging findings, the individual preference or acquisition
of medication other than by prescription was not cap-
tured in our study. Thus, their relevance on the decision
for or against OA remains unclear.
Conclusion
In the delivery of patient care, more than half of the pa-
tients with AF after stroke did not receive OA medica-
tion; 50% of these patients were above 81 years of age.
In balancing effectiveness versus risk to harm, safety
concerns prevail regarding therapeutic decisions. This is
predominantly due to the high proportion of elderly
patients receiving care. The factor of advanced age is
correlated with a decision against OA. Patients with de-
mentia were also less likely to receive OA. Even though
all our subjects were only slightly affected by stroke
(mRS ≤ 3), we noticed a decreased use of OA as there
was an increased worsening of the disability. In contrast,
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were more likely to receive OA as a treatment option.
As a result, it would be beneficial providing additional
education programs to non-specialists treating stroke
patients make them more aware of its clinical benefits
over other treatment options.
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